TAP Lupron approvals and audits
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
One-month and three-month formulations of TAP's GnRH agonist Lupron Depot are approved Sept. 21 for the initial management of endometriosis and management of recurrence of symptoms. On Oct. 3, the Department of Justice announced that TAP agreed to pay $875 mil. to resolve criminal charges related to violations of the Prescription Drug Marketing Act and the False Claims Act in Lupron prostate cancer promotions. The firm also agreed to annual audits of Lupron and Prevacid sales and marketing by independent reviewers
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.